The antisecretory effects of zaltidine, a novel long-acting H2-receptor antagonist, in healthy volunteers and in subjects with a past history of duodenal ulcer.

Abstract

The potency and duration of the antisecretory action of zaltidine, a novel H2-receptor antagonist, have been examined in healthy volunteers and in patients with previous duodenal ulceration. In eight healthy male volunteers single oral doses of 5 mg, 25 mg and 100 mg produced dose-related inhibition of basal and pentagastrin-stimulated acid output (M.A.O.) with an estimated ID50 of 40 mg for the latter. In eight subjects with duodenal ulceration single 100 mg and 200 mg doses produced 85% and 97% inhibition of M.A.O. at peak (3 h post-dose) and 20% and 23% inhibition at 24 h, respectively; inhibition of basal acid output was 97% at 3 h and 50% at 24 h with both doses. The long duration of action of zaltidine is ascribed to its relatively slow elimination from the plasma.

• Authors: G Laferla, N Buchanan, J Hearns, G P Crean, K E McColl, A T Clucas
• Journal: British journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 22 Issue 4 Pg. 395-9 (Oct 1986) ISSN: 0306-5251 [Print] England
• PMID: 2876724 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Guanidines
• Histamine H2 Antagonists
• zaltidine
• Pentagastrin

Topics

• Adult
• Clinical Trials as Topic
• Double-Blind Method
• Duodenal Ulcer (metabolism)
• Gastric Acid (metabolism)
• Guanidines (pharmacology)
• Histamine H2 Antagonists (pharmacology)
• Humans
• Male
• Middle Aged
• Pentagastrin (metabolism)
• Random Allocation